Connect Biopharma to present positive Rademikibart data in type 2 asthma at EAACI 2025
Connect Biopharma Holdings Limited (a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced two oral presentations… read more.

